PA8.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 nov 2023 @ 17:36):

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide...

Stats
Dagens volum	5 275.00
Gjennomsnittsvolum	18 739.00
Markedsverdi	2.71M
EPS	€0 ( 2024-04-21 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.130
ATR14	€0.380 (105.56%)

Volum Korrelasjon

Lang: -0.58 (weak negative)

Kort: 0.13 (neutral)

Signal:(15.842) Neutral

Paion AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Paion AG Korrelasjon - Valuta/Råvare

-0.64
( weak negative )

-0.62
( weak negative )

0.61
( weak )

-0.55
( weak negative )

-0.23
( neutral )

0.11
( neutral )

Paion AG Økonomi

Annual	2022
Omsetning:	€33.25M
Bruttogevinst:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2022
Omsetning:	€33.25M
Bruttogevinst:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2021
Omsetning:	€7.13M
Bruttogevinst:	€4.05M (56.83 %)
EPS:	€-0.310

FY	2020
Omsetning:	€19.66M
Bruttogevinst:	€19.66M (100.00 %)
EPS:	€0.0295

Financial Reports:

No articles found.

Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.